Basel, 10 February 2014
Upcoming changes to the Roche ADR (RHHBY)
Roche (SIX: RO, ROG; OTCQX: RHHBY) plans to implement a change to its US ADR programme (RHHBY, CUSIP 771195104) in the near future. The planned change comprises a change in the ADR ratio from now 4 (four) ADRs (RHHBY) per 1 (one) underlying non-voting equity security (ROG) to future 8 (eight) RHHBYs per 1 (one) ROG. It is estimated that the first day of trading with the new ADR ratio will be Thursday 27 February 2014. This ratio change will have no impact on the number of securities outstanding of the Roche voting share (RO) or the Roche non-voting equity security (ROG).
The timeline for the ADR split is expected to be as follows:
ADR split record date1 20 February 2014
ADR split payable date 26 February 2014
ADR split ex-date2 27 February 2014
1Last date on which the holder’s name must be registered on the books of the Depositary in order to receive ADR distribution
2Date on which the ADR begins trading without ADR distribution (date on which the ADR will begin trading at half the price)
Subject to the approval by the Annual General Meeting on 4 March 2014 of the 2013 financial year dividend, the upcoming dividend will be paid to holders of the Roche ADR (RHHBY) based on the new ADR ratio described above, but will take into account the holder’s ADR position after the split.
The Roche ADR (RHHBY) dates to 1992 and ADR trading was upgraded to OTCQX International Premier in 2007. J.P. Morgan acts as depositary bank for the Roche ADR programme.
Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and neuroscience. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. Roche’s personalised healthcare strategy aims at providing medicines and diagnostics that enable tangible improvements in the health, quality of life and survival of patients. Founded in 1896, Roche has been making important contributions to global health for more than a century. Twenty-four medicines developed by Roche are included in the WHO Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and chemotherapy.
In 2013 the Roche Group employed over 85,000 people worldwide, invested 8.7 billion Swiss francs in R&D and posted sales of 46.8 billion Swiss francs. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com.
All trademarks used or mentioned in this release are protected by law.